CohBar Inc
Change company Symbol lookup
Select an option...
CWBR CohBar Inc
CARR Carrier Global Corp
BRK.B Berkshire Hathaway Inc
PRA ProAssurance Corp
CAJFF Canon Inc
INSG Inseego Corp
LVRLF CordovaCann Corp
SRNE Sorrento Therapeutics Inc
JWN Nordstrom Inc
BKKXF Bangkok Expressway and Metro PCL
Go

Health Care : Biotechnology | Small Cap Value
Company profile

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.

Price
Delayed
$1.27
Day's Change
0.0144 (1.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.29
Day's Low
1.23
Volume
(Below Average)

Today's volume of 222,778 shares is on pace to be lower than CWBR's 10-day average volume of 593,489 shares.

222,778

Display:

Providers:

UpdateCancel
6 providers
November 19, 2020
CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

November 16, 2020
CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the third quarter ended September 30...(Globe Newswire)

CohBar, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 16, 2020 / CohBar, Inc. (NASDAQ:CWBR) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 16, 2020 at 5:00 PM Eastern Time. (Accesswire)

November 02, 2020
CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2020 financial...(Globe Newswire)

October 29, 2020
CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced it will host a Key Opinion Leader (KOL) webinar on the current...(Globe Newswire)

October 27, 2020
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief...(Globe Newswire)

October 26, 2020
CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data demonstrating that combination of a CB5138...(Globe Newswire)

October 15, 2020
CohBar to Present at the BIO-Europe Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

October 08, 2020
CohBar's CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be a...(Globe Newswire)

October 05, 2020
CohBar to Present at the BIO Investor Forum

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

September 29, 2020
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

September 10, 2020
CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

September 03, 2020
CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

August 28, 2020
CohBar Announces Closing of Public Offering of Common Stock and Warrants

CohBar, Inc. (NASDAQ: CWBR) (the "Company"), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the closing of its previously announced...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.